Anzeige
Meldung des Tages: Erste Psilocybin-Behandlungen laufen – warum steht Optimi noch bei Pennystock-Level?!

BioVersys News

Aktie
WKN:  A410LA ISIN:  CH0210362643 Branche:  Biotechnologie Land:  Schweiz
24,40 CHF
+0,60 CHF
+2,52%
26,846 € 27.02.26
Depot/Watchlist
Marktkapitalisierung *
155,52 Mio. €
Streubesitz
24,62%
KGV
-
Index-Zuordnung
-

BioVersys News

19.02.26 - EQS
BioVersys and partners’ phase 2a tuberculosis trial results published in New England Journal of Medicine
BioVersys AG / Key word(s): Scientific publication BioVersys and partners’ phase 2a tuberculosis trial results published in New England Journal of Medicine 19.02.2026 / 07:17 ...
11.12.25 - EQS
BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update
BioVersys AG / Key word(s): Study BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update 11-Dec-2025 / 07:00 CET/CEST Release of an ad hoc ...
10.11.25 - EQS
BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network
BioVersys AG / Key word(s): Study/Funds BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network 10-Nov-2025 / 07:00 CET/CEST Release of an ad hoc ...
06.11.25 - EQS
Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in CHInA
BioVersys AG / Key word(s): Study Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in CHInA 06-Nov-2025 / 07:00 CET/CEST Release of ...
05.11.25 - EQS
Bioversys to Present at Stifel 2025 Annual Healthcare Conference in New york
BioVersys AG / Key word(s): Conference Bioversys to Present at Stifel 2025 Annual Healthcare Conference in New york 05.11.2025 / 07:00 CET/CEST
03.11.25 - EQS
Bioversys announces appointment of anti-infective expert Dr. Daniel Ritz as Chief Scientific Officer and retirement of Dr. Sergio Lociuro
BioVersys AG / Key word(s): Personnel Bioversys announces appointment of anti-​infective expert Dr. Daniel Ritz as Chief Scientific Officer and retirement of Dr. Sergio Lociuro ...
10.09.25 - EQS
Bioversys reports corporate highlights and key financials for the first half 2025
BioVersys AG / Key word(s): Half Year Results Bioversys reports corporate highlights and key financials for the first half 2025 10-Sep-2025 / 07:00 CET/CEST Release of an ad hoc ...
29.08.25 - EQS
Bioversys To announce its FIrst half 2025 financial results, Provide a business update And Host a Conference call
BioVersys AG / Key word(s): Half Year Results Bioversys To announce its FIrst half 2025 financial results, Provide a business update And Host a Conference call 29.08.2025 / 07:00 ...
27.08.25 - EQS
BioVersys receives EMA Orphan Designation for the combination of alpibectir and ethionamide for the treatment of tuberculosis
BioVersys AG / Key word(s): Regulatory Admission BioVersys receives EMA Orphan Designation for the combination of alpibectir and ethionamide for the treatment of tuberculosis ...
02.07.25 - EQS
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECTRUM NON-TUBERCULOUS MYCOBACTERIA (NTM) CLINICAL CANDIDATE
BioVersys AG / Key word(s): Agreement/Partnership BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-​SPECTRUM NON-...
30.06.25 - EQS
BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS
BioVersys AG / Key word(s): AGMEGM BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS 30-Jun-2025 / 07:00 CET/CEST Release ...
03.06.25 - EQS
BioVersys publishes Invitation to its ANNUAL GENERAL MEETING OF SHAREHOLDERS 2025
BioVersys AG / Key word(s): AGMEGM BioVersys publishes Invitation to its ANNUAL GENERAL MEETING OF SHAREHOLDERS 2025 03-Jun-2025 / 07:00 CET/CEST Release of an ...
28.04.25 - EQS
BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter on May 7, 2025
BioVersys AG / Key word(s): Conference BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem ...
08.04.25 - EQS
BIOVERSYS TO PRESENT BV100 PHASE 2 DATA AT 35TH ESCMID GLOBAL 2025
BioVersys AG / Key word(s): Conference BIOVERSYS TO PRESENT BV100 PHASE 2 DATA AT 35TH ESCMID GLOBAL 2025 08.04.2025 / 07:00 CET/CEST
31.03.25 - EQS
BIOVERSYS ANNOUNCES IMPORTANT BV100 PATENT GRANTED BY CHINESE PATENT OFFICE
BioVersys AG / Key word(s): Patent BIOVERSYS ANNOUNCES IMPORTANT BV100 PATENT GRANTED BY CHINESE PATENT OFFICE 31-March-2025 / 07:00 CET/CEST Release of ...
26.03.25 - EQS
BIOVERSYS REPORTS CORPORATE HIGHLIGHS AND KEY FINANCIALS FOR THE FULL YEAR 2024
BioVersys AG / Key word(s): Annual Results BIOVERSYS REPORTS CORPORATE HIGHLIGHS AND KEY FINANCIALS FOR THE FULL YEAR 2024 26-March-2025 / 07:00 CET/CEST ...
19.03.25 - EQS
FIRST EVER PATIENT DOSED WITH ALPIBECTIR-ETHIONAMIDE IN COMBINATION WITH FIRST-LINE TB DRUGS IN A 14-DAY PHASE 2 CLINICAL TRIAL
BioVersys AG / Key word(s): Miscellaneous FIRST EVER PATIENT DOSED WITH ALPIBECTIR-​ETHIONAMIDE IN COMBINATION WITH FIRST-​LINE TB DRUGS IN A 14-DAY PHASE 2 ...
14.03.25 - EQS
BIOVERSYS ANNOUNCES REPORTING DATE FOR FULL-YEAR 2024 FINANCIAL RESULTS AND EVENT DETAILS
BioVersys AG / Key word(s): Annual Results BIOVERSYS ANNOUNCES REPORTING DATE FOR FULL-YEAR 2024 FINANCIAL RESULTS AND EVENT DETAILS 14.03.2025 / 07:00 ...
10.03.25 - EQS
Bioversys announces partial exercise of over-allotment option
BioVersys AG / Key word(s): IPO Bioversys announces partial exercise of over-​allotment option 10-March-2025 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to ...

Newssuche

Videos

newspaper
25.02.26
So beeinflussen Margins DEIN Trading
Börsentäglich ab 18 Uhr Feierabend-​Trading Live. Teilnahme kostenlos mit diesem Link ... Mehr »